Thermo Fisher Scientific Inc. (NYSE:TMO) insider Gregory J. Herrema sold 17,235 shares of the stock in a transaction dated Thursday, November 29th. The stock was sold at an average price of $247.00, for a total transaction of $4,257,045.00. Following the completion of the transaction, the insider now directly owns 26,446 shares of the company’s stock, valued at approximately $6,532,162. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of NYSE TMO traded up $0.98 during mid-day trading on Friday, hitting $249.55. 2,201,669 shares of the stock were exchanged, compared to its average volume of 1,460,683. The firm has a market cap of $99.60 billion, a price-to-earnings ratio of 26.30, a PEG ratio of 1.79 and a beta of 1.08. The company has a current ratio of 1.84, a quick ratio of 1.27 and a debt-to-equity ratio of 0.66. Thermo Fisher Scientific Inc. has a twelve month low of $181.51 and a twelve month high of $250.75.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 24th. The medical research company reported $2.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.55 by $0.07. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.70 billion. Thermo Fisher Scientific had a net margin of 10.75% and a return on equity of 16.49%. The company’s revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the business posted $2.31 earnings per share. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 11.04 earnings per share for the current year.
Thermo Fisher Scientific announced that its board has authorized a stock buyback program on Friday, September 7th that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the medical research company to reacquire up to 2.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.
Several research analysts recently issued reports on TMO shares. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $261.00 price target for the company in a research report on Monday, August 6th. Goldman Sachs Group lowered shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research report on Monday, September 17th. Barclays increased their price target on shares of Thermo Fisher Scientific from $250.00 to $275.00 and gave the stock an “overweight” rating in a research report on Monday, September 24th. UBS Group started coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, October 9th. They issued a “buy” rating and a $295.00 price target for the company. Finally, Citigroup increased their price target on shares of Thermo Fisher Scientific from $260.00 to $280.00 and gave the stock a “buy” rating in a research report on Wednesday, October 10th. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $263.45.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Pitcairn Co. increased its holdings in shares of Thermo Fisher Scientific by 1.3% in the second quarter. Pitcairn Co. now owns 16,871 shares of the medical research company’s stock valued at $3,495,000 after purchasing an additional 215 shares in the last quarter. Hall Capital Management Co. Inc. increased its holdings in shares of Thermo Fisher Scientific by 6.2% in the third quarter. Hall Capital Management Co. Inc. now owns 3,780 shares of the medical research company’s stock valued at $923,000 after purchasing an additional 220 shares in the last quarter. Nvwm LLC increased its holdings in shares of Thermo Fisher Scientific by 6.1% in the second quarter. Nvwm LLC now owns 4,231 shares of the medical research company’s stock valued at $877,000 after purchasing an additional 242 shares in the last quarter. Tiedemann Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 19.4% in the second quarter. Tiedemann Advisors LLC now owns 1,518 shares of the medical research company’s stock valued at $315,000 after purchasing an additional 247 shares in the last quarter. Finally, Chesapeake Wealth Management increased its holdings in shares of Thermo Fisher Scientific by 6.0% in the second quarter. Chesapeake Wealth Management now owns 4,393 shares of the medical research company’s stock valued at $910,000 after purchasing an additional 249 shares in the last quarter. 85.47% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece of content was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/11/30/insider-selling-thermo-fisher-scientific-inc-tmo-insider-sells-17235-shares-of-stock.html.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: Stock Selection – What is cash flow?
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.